XenoHelix announced on April 16, 2025, that it successfully hosted an exclusive seminar at Dubai Derma 2025, the largest dermatology and skincare exhibition in the Middle East. The seminar focused on the theme: "The Application of Next-Generation Exosomes: Transforming microRNA and Exosome-Based Technologies into Cosmetic Materials."

 

The seminar was held at the invitation of XenoHelix’s Middle Eastern business partner, drawing a large audience of medical professionals, global skincare experts, and leading international distributors.

 

During the session, CEO Sung-Wook Yang highlighted the technological superiority of using the company's advanced exosome materials. He emphasized the innovation and competitive edge behind XenoHelix’s premium functional product lineups, including ExoGene, ExoLift, ExoVital, and ExoScalp.

XenoHelix has secured pioneering core technology (XENOPURE) that isolates nucleic acids and exosomes with high purity and efficiency from ultra-low volume samples for precision molecular diagnostics. The company has swiftly leveraged and expanded this diagnostic-grade platform into its high-growth skin booster business.

 

At the seminar, XenoHelix introduced its proprietary technology capable of extracting exosomes under specific photosynthetic environments to manufacture 'plant-derived, efficacy-enhanced exosomes.' The company also showcased its unique capability to extract active substances and microRNA from within these exosomes to conduct comprehensive characterization and quality analysis. Furthermore, updates on the company’s ongoing PDRN (Polydeoxyribonucleotide) business initiatives were shared with the global audience.

 

"Attending Dubai Derma allowed us to experience firsthand the incredible global status of K-Beauty," said CEO Sung-Wook Yang. "We received overwhelming interest and numerous proposals for follow-up meetings from the attendees, making this a pivotal opportunity to validate the immense growth potential of our skin booster business in the global market."